Incruse Ellipta vs. Symbicort

Incruse Ellipta (umeclidinium) Inhalation Powder and Symbicort (budesonide and formoterol fumarate dihydrate) are used for maintenance treatment and prevention of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Symbicort is also used to prevent bronchospasm in people with asthma.

Incruse Ellipta and Symbicort belong to different drug classes. Incruse Ellipta is an anticholinergic drug and Symbicort is a combination of a steroid and a long-acting bronchodilator.

Side effects of Incruse Ellipta and Symbicort that are similar include stuffy or runny nose, sore throat, joint pain, muscle pain, and stomach pain or upset.

Side effects of Incruse Ellipta that are different from Symbicort include upper respiratory infection, cough, tooth pain, bruising or dark areas of skin, chest pain, fast or irregular heartbeat, and constipation.

Side effects of Symbicort that are different from Incruse Ellipta include headache, nausea, vomiting, diarrhea, back pain, and changes in your voice.

Incruse Ellipta may interact with other anticholinergic drugs.

Symbicort may interact with antibiotics, antifungal medications, MAO inhibitors, antidepressants, beta-blockers, and diuretics (water pills).

Common side effects of Incruse Ellipta include:

• upper respiratory infection,
• stuffy or runny nose,
• cough,
• sore throat,
• joint pain,
• muscle pain,
• tooth pain,
• stomach pain,
• bruising or dark areas of skin,
• chest pain,
• fast or irregular heartbeat, and
• constipation.

Common side effects of Symbicort include:

• headache,
• throat irritation,
• nausea,
• vomiting,
• stomach upset,
• diarrhea,
• back pain,
• stuffy nose,
• muscle or joint pain, or
• changes in your voice.

Tell your doctor if you experience unlikely but serious side effects of Symbicort including:

• white patches on tongue or in mouth,
• signs of infection (such as fever, persistent sore throat),
• mental/mood changes (such as nervousness),
• trouble sleeping,
• vision problems (such as blurred vision),
• increased thirst or urination,
• muscle cramps, or
• shaking (tremors).

Incruse Ellipta (umeclidinium) Inhalation Powder is an anticholinergic drug used for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

Symbicort (budesonide and formoterol fumarate dihydrate) is a combination of a steroid and a long-acting bronchodilator used to prevent bronchospasm in people with asthma or chronic obstructive pulmonary disease (COPD).

Symbicort combines an inhaled corticosteroid medicine, budesonide and a LABA medicine, formoterol.

• Inhaled corticosteroids help to decrease inflammation in the lungs. Inflammation in the lungs can lead to breathing problems.
• LABA medicines are used in people with chronic obstructive pulmonary disease (COPD) and asthma. LABA medicines help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe. In severe cases, wheezing can stop your breathing and may lead to death if not treated right away.

Incruse Ellipta may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use. During pregnancy, Incruse Ellipta should be taken only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Symbicort may interact with antibiotics, antifungal medication, MAO inhibitor, antidepressants, beta-blockers, or diuretics (water pills). Tell your doctor all medications you are taking. During pregnancy, Symbicort should be used only when prescribed. Budesonide passes into breast milk. It is unknown if formoterol passes into breast milk. Consult your doctor before breastfeeding.

Incruse Ellipta (umeclidinium 62.5 mcg) should be administered as 1 inhalation dose once daily by the orally inhaled route only. Incruse Ellipta may interact with other anticholinergic drugs. Tell your doctor all medications and supplements you use.

For patients 12 years of age and older, the dosage of Symbicort is 2 inhalations twice daily (morning and evening, approximately 12 hours apart).